Latest Werewolf Therapeutics News & Updates

See the latest news and media coverage for Werewolf. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Werewolf Therapeutics (Werewolf)

Cancer immunotherapy biotechnology company

werewolftx.com
Headquarters
Watertown, United States
Company type
Public company
Number of employees
20–50
Industry
Pharmaceuticals

Last updated

Latest news about Werewolf Therapeutics (Werewolf)

In short: Werewolf agreed to merge with Ambros in a $500M all-stock deal, becoming Ambros Therapeutics, with $150M PIPE financing.

Company announcements

Werewolf

Werewolf sells assets to EMD for $33M

The company receives upfront and completion payments in exchange for INDUCER and INDUKINE platforms, while retaining clinical programs WTX-124 and WTX-330.

Werewolf

Werewolf Therapeutics reports first quarter 2026 financial results

The firm sold JZP898 development rights to Jazz Pharmaceuticals, repaid its K2 loan, and maintains $46.5 million in cash amid a $13.5 million quarterly net loss.

Unlock all announcements with a

Media coverage

Barron's

Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc. research and ratings by Barron's. View HOWL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Unlock all articles with a

Never miss news about Werewolf

Track Werewolf and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Werewolf competitors & trending companies

Browse news for competitors to Werewolf and other trending companies.